Genprex (GNPX) Projected to Post Earnings on Friday

Posted by Hanz Christensen on Mar 26th, 2026

Genprex (NASDAQ:GNPX – Get Free Report) is anticipated to post its resultson Friday, March 27th. Analysts expect Genprex to post earnings of ($13.00) per share for the quarter.

Genprex Stock Up 2.6%

Shares of NASDAQ GNPX opened at $1.94 on Thursday. The company has a market capitalization of $6.05 million, a PE ratio of -0.07 and a beta of -0.77. Genprex has a twelve month low of $1.71 and a twelve month high of $55.00. The firm has a fifty day simple moving average of $2.21 and a 200 day simple moving average of $5.15.

Institutional Investors Weigh In On Genprex

A hedge fund recently raised its stake in Genprex stock. Susquehanna International Group LLP grew its position in Genprex (NASDAQ:GNPX – Free Report) by 11.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 340,056 shares of the company’s stock after purchasing an additional 35,661 shares during the period. Susquehanna International Group LLP owned about 27.20% of Genprex worth $58,000 at the end of the most recent reporting period. 14.05% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Genprex in a research report on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has an average rating of “Sell”.

View Our Latest Research Report on GNPX

Genprex Company Profile

(Get Free Report)

Genprex, Inc is a clinical-stage gene therapy company focused on developing novel, first-in-class treatments for cancer and diabetes. Its proprietary technology employs targeted nanoparticle delivery of therapeutic genes designed to address the underlying genetic drivers of disease. Genprex’s lead oncology candidate, Oncoprex immunogene therapy, is being evaluated for patients with non-small cell lung cancer, with the goal of restoring tumor suppressor function and enhancing response to existing targeted therapies in clinical trials across the United States.

In addition to its oncology pipeline, Genprex is advancing GPTX-203, a gene therapy candidate aimed at improving pancreatic beta-cell function in patients with type 1 diabetes.